project id: TCGA-BLCA; case submitter id: TCGA-2F-A9KR; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.45; rna integrity number: 7.7; age at index: 59; days to birth: -21848; days to death: 3183; ethnicity: not reported; gender: female; race: not reported; vital status: Dead; year of birth: 1941; age at diagnosis: 21848; ajcc clinical t: T2; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3a; ajcc staging system edition: 5th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 3148.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8130/3; primary diagnosis: Papillary transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2000; alcohol history: Not Reported; cigarettes per day: 1.2328767123287672; pack years smoked: 22.5; is ffpe: false; composition: Not Reported; days to collection: 4919; days to sample procurement: 0; initial weight: 650.0; portion submitter id: TCGA-2F-A9KR-01A-11; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 70.0;